profit from every $100 of sales.
$0$100
Wave Life Sciences
$3.13-0.79% today
-6.1% in 1 year
1-year low $3.091-year high $10.66
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Wave Life Sciences sold, what it kept, and what it did with the cash.
Sales went from $3.65 million in 2022 to $42.7 million in 2025, with -$204 million of profit last year.
SalesProfit
Wave Life Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Wave Life Sciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Wave Life Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4 | 113 | 108 | 43 | |
| – | – | – | – | |
| -163 | -68 | -110 | -215 | |
| -153 | -59 | -102 | -207 | |
| -162 | -58 | -97 | -204 | |
| -2.05 | -0.54 | -0.70 | -1.21 | |
| – | – | – | – | |
| -4,459.3% | -60.0% | -101.9% | -504.1% | |
| -4,434.7% | -50.8% | -89.6% | -478.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 146 | 275 | 352 | 638 |
| Cash | 88 | 200 | 302 | 602 |
| Total debt | 38 | 32 | 25 | 18 |
| Total liabilities | 191 | 235 | 143 | 120 |
| -45 | 40 | 210 | 518 | |
| 79 | 106 | 138 | 169 | |
| – | -74.9% | -37.1% | -31.7% | |
| 358.9% | -145.1% | -46.3% | -39.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -128 | -19 | -151 | -187 | |
| 1 | 1 | 1 | 1 | |
| -129 | -21 | -152 | -188 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 17 | 10 | 13 | 25 |
Valuation
- –
- –
- –
- 2.8×
- 14.4×
- –
- –
- -30.5%
- -33.1%
- 0.0%
Profitability
- 93.8%
- -504.1%
- -478.3%
- -253.6%
- -36.3%
- 361.9%
- -56.4%
- -31.5%
- -36.9%
- 264.1%
Growth
- +127.1%
- –
- −23.4%
- –
- +34.3%
Financial health
- -2.8×
- 0.03
- 2.7%
- –
- 11.26
- 11.26
- 0.12
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 952
Top 4%of 886
Bottom 2%of 987
What analysts expect
- Average price target
- $26.69
- Range
- $13.00 – $43.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | -0.13 | -0.34 | +61.8% |
| Feb 26, 2026 | -0.30 | -0.28 | −7.1% |
| Nov 10, 2025 | -0.32 | -0.30 | −6.7% |
| Jul 30, 2025 | -0.31 | -0.29 | −6.9% |
| May 8, 2025 | -0.29 | -0.27 | −7.4% |
| Mar 4, 2025 | 0.17 | -0.17 | +200.0% |
| Nov 12, 2024 | -0.47 | -0.28 | −67.9% |
| Aug 8, 2024 | -0.25 | -0.21 | −19.0% |
News
Real estate stocks gain as the Blue Wave sends Treasury yields lowerSeeking Alpha · Nov 7, 2026Evercore Names 5 Tech Stocks to Own After Blue WaveYahoo Finance · Nov 5, 2026Alphabet, Amazon, and Microsoft All Surged Today. You Can Thank the Big Blue Wave.Yahoo Finance · Nov 4, 2026Ironically, the Blue Wave Could Make Hyperscalers “Good Businesses Again” by Forcing Capex DisciplineYahoo Finance · Nov 4, 2026Hospital stocks rally while drugmakers brace for scrutiny. Here’s what the Democratic wave means for healthcare.MarketWatch · Nov 4, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
47No pass
Philip Fisher
54No pass
Peter Lynch
53No pass
Joel Greenblatt
4No pass
Charlie Munger
47No pass
Terry Smith
46No pass
Questions about Wave Life Sciences
Is Wave Life Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Wave Life Sciences AI analysis
What does Wave Life Sciences do?
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is in Biotechnology.
Does Wave Life Sciences pay a dividend?
No. Wave Life Sciences does not pay a dividend at the moment.
Is Wave Life Sciences stock halal?
No. Wave Life Sciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 98% of its market value, at or above the 33% limit. How we check
How has Wave Life Sciences stock done over the past year?
Down 6.1% over the past twelve months, to $3.13. It traded between $3.09 and $10.66 and is 70.6% below its high.
Who are Wave Life Sciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Wave Life Sciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.